Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QAR3 | ISIN: US0044685008 | Ticker-Symbol: SP4P
Tradegate
21.01.25
20:06 Uhr
2,865 Euro
-0,210
-6,83 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ACHIEVE LIFE SCIENCES INC Chart 1 Jahr
5-Tage-Chart
ACHIEVE LIFE SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,7102,81021.01.
2,7102,77021.01.

Aktuelle News zur ACHIEVE LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiACHV-Aktie erreicht 52-Wochen-Tief bei 3,01 US-Dollar1
DiACHV Stock Touches 52-Week Low at $3.01 Amid Market Challenges1
10.01.ACHIEVE LIFE SCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans1
10.01.ACHV-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar1
10.01.Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors5
10.01.ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report-
08.01.Achieve Life Sciences announces critical milestone successfully reached in ORCA-OL cytisinicline clinical trial required for NDA submission (POSITIVE)4
ACHIEVE LIFE SCIENCES Aktie jetzt für 0€ handeln
07.01.Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission82Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term Exposure...
► Artikel lesen
02.01.Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1?10
09.12.24ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report1
09.12.24Achieve Life Sciences Appoints Mark Oki As New CFO-
09.12.24Achieve Life Sciences appoints Mark Oki as CFO3
09.12.24Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer108SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization...
► Artikel lesen
05.12.24ACHIEVE LIFE SCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans-
03.12.24Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA12
07.11.24ACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report4
07.11.24ACHIEVE LIFE SCIENCES, INC. - 8-K, Current Report3
23.10.24Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting9
16.10.24Achieve Life Sciences appoints new Chief Commercial Officer2
16.10.24Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline115SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2